Targets › THBD
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Aug 2028.
Endothelial cell receptor that plays a critical role in regulating several physiological processes including hemostasis, coagulation, fibrinolysis, inflammation, and angiogenesis. Acts as a cofactor for thrombin activation of protein C/PROC on the surface of vascular endothelial cells leading to initiation of the activated protein C anticoagulant pathway. (UniProt, P07204)
Open in Phaseline: the race on THBD, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Recombinant human Thrombomodulin (rhTM) Thrombomodulin mimetic with anticoagulant and anti-inflammatory properties | THBD | Phase 2 | Sepsis | Aug 2028 |
Sepsis (1)
mixed (1)
Assistance Publique - Hôpitaux de Paris (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.